Trials / Unknown
UnknownNCT03927352
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
A Phase 3, Randomized, Double-blind Study Evaluating the Efficacy and Safety of SCT630 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCT630 | Administered by subcutaneous injection |
| BIOLOGICAL | Adalimumab | Administered by subcutaneous injection |
Timeline
- Start date
- 2019-09-05
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
- First posted
- 2019-04-25
- Last updated
- 2021-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03927352. Inclusion in this directory is not an endorsement.